{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:39:06Z","timestamp":1755225546510,"version":"3.43.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,13]]},"DOI":"10.7759\/cureus.89983","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T13:14:50Z","timestamp":1755090890000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Treatment Response in Patients With Diffuse Large B-cell Non-Hodgkin Lymphoma Using the Deauville Criteria: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"David","family":"Gutierrez Albenda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Solano-Brenes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson Mauricio","family":"S\u00e1nchez Hidalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Natalia","family":"Rodr\u00edguez Varela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Ulate Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues, review","author":"Swerdlow SH","year":"2017","unstructured":"Swerdlow SH, Campo E, Harris NL, et al.. WHO classification of tumours of haematopoietic and lymphoid tissues, review. International Agency for Research on Cancer, Lyon, France; 2017."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel V","year":"2020","unstructured":"Poeschel V, Held G, Ziepert M, et al.. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2020, 394:2271-81. 10.1016\/S0140-6736(19)33008-9","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e19749","article-title":"Prognostic value of whole-body dynamic (18)F-FDG PET\/CT Patlak in diffuse large B-cell lymphoma","volume":"9","author":"Yin J","year":"2023","unstructured":"Yin J, Wang H, Zhu G, Chen N, Khan MI, Zhao Y. Prognostic value of whole-body dynamic (18)F-FDG PET\/CT Patlak in diffuse large B-cell lymphoma. Heliyon. 2023, 9:e19749. 10.1016\/j.heliyon.2023.e19749","journal-title":"Heliyon"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2015150689","article-title":"Diffuse large B-cell lymphoma: prospective multicenter comparison of early interim FLT PET\/CT versus FDG PET\/CT with IHP, EORTC, Deauville, and PERCIST criteria for early therapeutic monitoring","volume":"280","author":"Minamimoto R","year":"2016","unstructured":"Minamimoto R, Fayad L, Advani R, et al.. Diffuse large B-cell lymphoma: prospective multicenter comparison of early interim FLT PET\/CT versus FDG PET\/CT with IHP, EORTC, Deauville, and PERCIST criteria for early therapeutic monitoring. Radiology. 2016, 280:220-9. 10.1148\/radiol.2015150689","journal-title":"Radiology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s43055-020-00353-5","article-title":"PET\/CT vs CECT in assessment of therapeutic response in lymphoma","volume":"51","author":"Yassin A","year":"2020","unstructured":"Yassin A, El Sheikh RH, Ali MM. PET\/CT vs CECT in assessment of therapeutic response in lymphoma. Egypt J Radiol Nucl Med. 2020, 51:238. 10.1186\/s43055-020-00353-5","journal-title":"Egypt J Radiol Nucl Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-024-05905-0","article-title":"Survival prediction in diffuse large B-cell lymphoma patients: multimodal PET\/CT deep features radiomic model utilizing automated machine learning","volume":"150","author":"Chen J","year":"2024","unstructured":"Chen J, Lin F, Dai Z, Chen Y, Fan Y, Li A, Zhao C. Survival prediction in diffuse large B-cell lymphoma patients: multimodal PET\/CT deep features radiomic model utilizing automated machine learning. J Cancer Res Clin Oncol. 2024, 150:452. 10.1007\/s00432-024-05905-0","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030601","article-title":"FDG-PET imaging for Hodgkin and diffuse large B-cell lymphoma-an updated overview","volume":"12","author":"Voltin CA","year":"2020","unstructured":"Voltin CA, Mettler J, Grosse J, et al.. FDG-PET imaging for Hodgkin and diffuse large B-cell lymphoma-an updated overview. Cancers (Basel). 2020, 12:10.3390\/cancers12030601","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193311","article-title":"Using Deauville scoring to guide consolidative radiotherapy in diffuse large B-cell lymphoma","volume":"16","author":"Yau CE","year":"2024","unstructured":"Yau CE, Low CE, Ong WS, et al.. Using Deauville scoring to guide consolidative radiotherapy in diffuse large B-cell lymphoma. Cancers (Basel). 2024, 16:10.3390\/cancers16193311","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/mp.14847","article-title":"Diffuse large B-cell lymphoma segmentation in PET-CT images via hybrid learning for feature fusion","volume":"48","author":"Yuan C","year":"2021","unstructured":"Yuan C, Zhang M, Huang X, et al.. Diffuse large B-cell lymphoma segmentation in PET-CT images via hybrid learning for feature fusion. Med Phys. 2021, 48:3665-78. 10.1002\/mp.14847","journal-title":"Med Phys"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1992624","article-title":"Prognostication of diffuse large B-cell lymphoma patients with Deauville score of 3 or 4 at end-of-treatment PET evaluation: a comparison of the Deauville 5-point scale and the \u0394SUVmax method","volume":"63","author":"Ng DZ","year":"2022","unstructured":"Ng DZ, Lee CY, Lam WW, et al.. Prognostication of diffuse large B-cell lymphoma patients with Deauville score of 3 or 4 at end-of-treatment PET evaluation: a comparison of the Deauville 5-point scale and the \u0394SUVmax method. Leuk Lymphoma. 2022, 63:256-9. 10.1080\/10428194.2021.1992624","journal-title":"Leuk Lymphoma"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005846","article-title":"Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP","volume":"137","author":"Freeman CL","year":"2021","unstructured":"Freeman CL, Savage KJ, Villa DR, et al.. Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2021, 137:929-38. 10.1182\/blood.2020005846","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002690","article-title":"End-of-treatment PET\/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA","volume":"5","author":"Kostakoglu L","year":"2021","unstructured":"Kostakoglu L, Martelli M, Sehn LH, et al.. End-of-treatment PET\/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. Blood Adv. 2021, 5:1283-90. 10.1182\/bloodadvances.2020002690","journal-title":"Blood Adv"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2023.12.003","article-title":"Integration of PET in DLBCL","volume":"60","author":"Lewis KL","year":"2023","unstructured":"Lewis KL, Trotman J. Integration of PET in DLBCL. Semin Hematol. 2023, 60:291-304. 10.1053\/j.seminhematol.2023.12.003","journal-title":"Semin Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7506","article-title":"Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL > 60 study of the DSHNHL","volume":"35","author":"Pfreundschuh M","year":"2017","unstructured":"Pfreundschuh M, Christofyllakis K, Altmann B, et al.. Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL > 60 study of the DSHNHL. J. Clin. Oncol. 2017, 35:7506. 10.1200\/JCO.2017.35.15_suppl.7506","journal-title":"J. Clin. Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial","volume":"36","author":"D\u00fchrsen U","year":"2018","unstructured":"D\u00fchrsen U, M\u00fcller S, Hertenstein B, et al.. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018, 36:2024-34. 10.1200\/JCO.2017.76.8093","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/397882-assessment-of-treatment-response-in-patients-with-diffuse-large-b-cell-non-hodgkin-lymphoma-using-the-deauville-criteria-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T13:14:51Z","timestamp":1755090891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/397882-assessment-of-treatment-response-in-patients-with-diffuse-large-b-cell-non-hodgkin-lymphoma-using-the-deauville-criteria-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.89983","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,13]]}}}